Professor, Medicine, Case Western Reserve University School of Medicine
Rheumatology
Dr. Gary S. Hoffman, MD
|
|
Give Review
Gary S. Hoffman, MD is an expert in the field of Rheumatology. He went to medical school at Virginia Commonwealth University School of Medicine. He received 2 awards: "CMS Meaningful Use Stage 1 Certification" and "Top MD". Gary S. Hoffman, MD has written publications. He has 95 publications published with PubMed. The lastest publication is: 'Establishing the feasibility of face transplantation in Granulomatosis with Polyangiitis (Wegener's).' Dr. Gary S. Hoffman accepts all Medicare patients.
Publications
- Establishing the feasibility of face transplantation in Granulomatosis with Polyangiitis (Wegener's).
- A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility.
- Genome-wide association study identifies susceptibility loci in IL6, RPS9/LILRB3, and an intergenic locus on chromosome 21q22 in Takayasu's Arteritis.
- Rituximab Versus Cyclophosphamide for ANCA-Associated Vasculitis with Renal Involvement.
- Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.
- Value of commonly measured laboratory tests as biomarkers of Disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis.
- Peripheral CD5(+) B-Cells in ANCA-associated vasculitis.
- Inflammatory Disease of the aorta: Patterns and classification of giant cell aortitis, Takayasu arteritis, and nonsyndromic aortitis.
- Vasculitis: determinants of Disease patterns.
- Rituximab with or without a conventional maintenance agent in relapsing granulomatosis with polyangiitis: A retrospective single-center study.
- Granulomatosis With Polyangiitis (Wegener's): Impact of Maintenance Therapy Duration.
- Recent advances in the medical management of Takayasu Arteritis: an update on use of biologic therapies.
- An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's).
- Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.
- New Features of Disease After Diagnosis in 6 Forms of Systemic Vasculitis.
- Efficacy of remission-induction regimens for ANCA-associated vasculitis.
- Serum proteins reflecting inflammation, injury and repair as biomarkers of Disease activity in ANCA-associated vasculitis.
- Urinary Biomarkers in Relapsing Antineutrophil Cytoplasmic Antibody-associated Vasculitis.
- 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.
- Letter to the Editor - in Response to the article by Faurschou and colleagues.
- Updating single-organ vasculitis.
- Association of Vascular Physical Examination Findings and Arteriographic Lesions in Large Vessel Vasculitis.
- IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis.
- Circulating markers of vascular injury and angiogenesis in ANCA-associated vasculitis.
- Assessment of health related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's).
- Tissue and serum markers of inflammation during the follow-up of patients with Giant-cell arteritis--a prospective longitudinal study.
- A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis.
- Relationship Between Markers of Platelet Activation and Inflammation with Disease Activity in Wegener's Granulomatosis.
- A pilot study to assess the frequency of Fibromyalgia, depression and sleep disorders in patients with Wegener granulomatosis.
- Therapeutic interventions for Systemic vasculitis.
- Alphaâ-antitrypsin deficiency-related alleles Z and S and the risk of Wegener's granulomatosis.
- Wegener's granulomatosis: clinical manifestations, differential diagnosis, and management of ocular and systemic Disease.
- Can't hear, can't see, and too sore to play.
- Serum chitotriosidase activity and Wegener's granulomatosis.
- Surgical interventions and local therapy for Wegener's granulomatosis.
- Persistent hematuria after induction of remission in Wegener granulomatosis: a therapeutic dilemma.
- Takayasu arteritis and giant cell arteritis: a spectrum within the same Disease?
- Gynecologic vasculitis: an analysis of 163 patients.
- Sinonasal Wegener granulomatosis: a single-institution experience with 120 cases.
- Determining the cause of isolated midline destructive lesions: comment on the clinical images presented by Kasifoglu et al.
- Anti-tumour necrosis factor therapy in patients with refractory Takayasu Arteritis: long-term follow-up.
- Intravenous immunoglobulin in Wegener's granulomatosis and microscopic polyangiitis.
- Discussion of the 2007 British Society for Rheumatology guidelines for management of ANCA-associated vasculitis.
- Vasculitis involving the breast: a clinical and histopathologic analysis of 34 patients.
- Single-organ vasculitis.
- Disease patterns in vasculitis-still a mystery.
- Takayasu Arteritis: what is the long-term prognosis?
- Substitution of methotrexate for cyclophosphamide in Wegener granulomatosis: a 12-year single-practice experience.
- Should induction therapy with high-dose glucocorticoids be the standard treatment for all patients with Giant cell arteritis?
- Limitations of therapy and a guarded prognosis in an American cohort of Takayasu Arteritis patients.
- Controversies in small vessel vasculitis--comparing the rheumatology and nephrology views.
- Antiplatelet and anticoagulant therapy in patients with Giant cell arteritis.
- Can methotrexate replace cyclophosphamide in the treatment of a subset of Wegener's granulomatosis and microscopic polyangiitis?
- Are there different forms of life in the antineutrophil cytoplasmic antibody universe?
- Determinants of vessel targeting in vasculitis.
- Implications of antineutrophil cytoplasmic antibody status when switching to maintenance therapy.
- Advances in the medical and surgical treatment of Takayasu Arteritis.
- Large-vessel vasculitis.
- An analysis of CTLA-4 and proinflammatory cytokine genes in Wegener's granulomatosis.
- Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu Arteritis.
- Identification of candidate microbial sequences from inflammatory lesion of Giant cell arteritis.
- Domains of health-related quality of life important to patients with Giant cell arteritis.
- Large-vessel vasculitis: unresolved issues.
- Prevalence of antineutrophil cytoplasmic antibodies in patients with various pulmonary Diseases or multiorgan dysfunction.
- Takayasu Arteritis: utility and limitations of magnetic resonance imaging in diagnosis and treatment.
- Patients' perceptions of the effects of systemic Lupus erythematosus on health, function, income, and interpersonal relationships: a comparison with Wegener's granulom...
- Treatment of Giant-cell arteritis: where we have been and why we must move on.
- Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener''s): long-term followup of a multicenter longitudinal cohort.
- Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener''s).
- Granulomatosis with polyangiitis (Wegener''s): an alternative name for Wegener''s granulomatosis.
- Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
- Limited utility of rapamycin in severe, refractory Wegener''s granulomatosis.
- Detection of Lupus anticoagulant and successful anticoagulation in familial Sneddon syndrome.
- Assessment of the item selection and weighting in the Birmingham vasculitis activity score for Wegener''s granulomatosis.
- The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener''s granulomatosis with and without his...
- Antiproteinase 3 antineutrophil cytoplasmic antibodies and Disease activity in Wegener granulomatosis.
- Effects of glucocorticoids on weight change during the treatment of Wegener''s granulomatosis.
- Antiendothelial cell antibodies in patients with Wegener''s granulomatosis: prevalence and correlation with Disease activity and manifestations.
- Infliximab for maintenance of glucocorticosteroid-induced remission of Giant cell arteritis: a randomized trial.
- The future of damage assessment in vasculitis.
- ANCA are detectable in nearly all patients with active severe Wegener''s granulomatosis.
- Current status of outcome measures in vasculitis: focus on Wegener''s granulomatosis and microscopic polyangiitis. Report from OMERACT 7.
- Herpes zoster in immunocompromised patients: incidence, timing, and risk factors.
- Solid malignancies among patients in the Wegener''s Granulomatosis Etanercept Trial.
- A serum proteomic approach to gauging the state of remission in Wegener''s granulomatosis.
- Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener''s Clinical Occurrence of Thrombosis (WeCLOT) S...
- Damage caused by Wegener''s granulomatosis and its treatment: prospective data from the Wegener''s Granulomatosis Etanercept Trial (WGET).
- Takayasu''s Arteritis: vascular interventions and outcomes.
- Wegener''s granulomatosis: survey of 701 patients in North America. Changes in outcome in the 1990s.
- Treatment of subglottic stenosis, due to Wegener''s granulomatosis, with intralesional corticosteroids and dilation.
- Crohn''s Disease plus Takayasu''s arteritis: more than coincidence?
- Relative importance of CCR5 and antineutrophil cytoplasmic antibodies in patients with Wegener''s granulomatosis.
- A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for Giant cell arteritis.
- Brain magnetic resonance imaging findings in ECT-induced delirium.
Schools
Virginia Commonwealth University School Of Medicine
Riverside Hospital
Dartmouth Hitchcock Clin
Dartmouth University
Procedures Preformed
- Joint Drainage
- Steroid Injection
Conditions Treated
- Adhesive Capsulitis
- Arthritis
- Bursitis
- Calcium Pyrophosphate Dihydrate Deposition Disease (CPPD)
- View All
Doctors Specialties
- Rheumatology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Top MD
Education
-
Dartmouth-Hitchcock Medical Center -
Virginia Commonwealth University School of Medicine
Hospital
-
Cleveland Clinic
Drug Facts
| NPI NUMBER | 1730143173 | |
| NPPES Provider LastName | HOFFMAN | |
| NPPES Provider FirstName | GARY | |
| NPPES Provider ZIPCode | 441950001 | |
| NPPES Provider State | OH | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 398.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1730143173 |
| Last Name Of The Provider | HOFFMAN |
| First Name Of The Provider | GARY |
| View All |
Similar Doctors
|
|
Dr. Soumya Chatterjee, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anna P. Koo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gheorghe P. Ignat, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cheung C. Yue, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anshul Rao, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carol A. Langford, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jason M. Springer, MD
This Doctor is OpenDoctor Recommended.
|